

Buckley Sean D.
Form 3
June 27, 2018

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Buckley Sean D.

(Last) (First) (Middle)

FIBROCELL SCIENCE,
INC.,Â 405 EAGLEVIEW
BLVD

(Street)

EXTON,Â PAÂ 19341

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

06/19/2018

3. Issuer Name and Ticker or Trading Symbol
Fibrocell Science, Inc. [FCSC]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner

☒ Officer ___ Other
(give title below) (specify below)

See Remarks

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
☒ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

Date Exercisable Expiration Date

3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)

Title Amount or Number of

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Edgar Filing: Buckley Sean D. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Option to Purchase Common Stock	Â (1)	01/14/2021	Common Stock	200	\$ 232.5	D	Â
Option to Purchase Common Stock	Â (2)	07/19/2023	Common Stock	334	\$ 82.35	D	Â
Option to Purchase Common Stock	Â (3)	04/01/2025	Common Stock	1,000	\$ 63.6	D	Â
Option to Purchase Common Stock	Â (4)	09/27/2026	Common Stock	2,229	\$ 11.25	D	Â
Option to Purchase Common Stock	Â (5)	03/16/2027	Common Stock	4,000	\$ 11.25	D	Â
Option to Purchase Common Stock	Â (6)	01/25/2028	Common Stock	5,000	\$ 3.45	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Buckley Sean D. FIBROCELL SCIENCE, INC. 405 EAGLEVIEW BLVD EXTON,Â PAÂ 19341	Â	Â	Â See Remarks	Â

Signatures

/s/ Sean D.
Buckley

06/27/2018

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vested as follows: (i) 100 shares on January 14, 2011 and (ii) 50 shares on each of January 14, 2012 and January 14, 2013.
- (2) The option vested in four equal installments on July 19, 2013, July 19, 2014, July 19, 2015 and July 19, 2016.
- (3) The option vests in four equal installments on April 1, 2016, April 1, 2017, April 1, 2018 and April 1, 2019 provided the reporting person is employed by Fibrocell Science, Inc., (the "Company") on each vesting date.
The option vests as follows (i) 558 shares on September 27, 2017 and (ii) the remaining shares in twelve equal quarterly installments
- (4) beginning on December 27, 2017 and ending on September 27, 2020 provided the reporting person is employed by the Company on each vesting date.
The option vests as follows: (i) 1,000 shares on March 16, 2018 and (ii) the remaining shares in twelve equal quarterly installments
- (5) beginning on June 16, 2018 and ending on March 16, 2021 provided the reporting person is employed by the Company on each vesting date.
- (6) The option vests as follows: (i) 1,250 shares on January 25, 2019 and (ii) the remaining shares in twelve equal quarterly installments beginning on April 25, 2019 and ending on January 25, 2022 provided the reporting person is employed by the Company on each vesting

date.

Â

Remarks:

ViceÂ PresidentÂ ofÂ BusinessÂ AdministrationÂ andÂ CorporateÂ Secretary

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.